Scrip Podcasts

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 9, 2026. This time—China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s...

Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult. As biomarkers, AI and precision medicine become increasingly integrated into clinical research, sponsors have new opportunities to strengthen study design, improve patient...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月2日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 谁在引领今年的并购步伐；罗氏（Roche）的研发管线重整；湿性黄斑变性（wet AMD）市场的洗牌；默克公司（Merck & Co.）撤回I-DXd申报；以及默克将Recarbio从市场上撤回。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/qui...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Oct. 2, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market.  Story links: https://insig...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国带来的变革效应；诺和诺德的新战略；罗氏的抗肥胖新药；安进在舍格伦综合征治疗领域的胜利；以及中国潜在的重磅药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WVD7A...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters.  Story links: https://insights.citeline.com/scrip/pod...

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-perfo...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；...

根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。 Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。 Story link: https://ins...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Zi...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-liste...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise. Story links: h...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。 Story link: https://insights.citeli...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in trans...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-fiv...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination...

China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies. In this episode, Meredith Landry, Managing Editor of Citeline's Custom Content, speaks with Catherine Xu, Senior Operations Manager at Novotech, about the factors reshaping China's role in global clinical deve...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 阿斯利康收紧人工智能支出；Argenx的产品管线聚焦产品开发；葛兰素史克在推进III期临床试验计划的同时削减成本；赛诺菲对产品管线进行重新评估；以及中国业务新公司2.0版。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/qu...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 31, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets. Story links: ht...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德在肥胖症治疗领域起诉礼来；特朗普针对仿制药采取新的关税措施；诺华CEO称赞日本、抨击德国的定价政策；制药行业会迎来“稀土时刻”吗？；以及欧洲生物技术行业正处于十字路口。 Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-m...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European b...